A Phase II study to evaluate DUR-928 for primary sclerosing cholangitis (PSC)

Trial Profile

A Phase II study to evaluate DUR-928 for primary sclerosing cholangitis (PSC)

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs DUR 928 (Primary)
  • Indications Primary sclerosing cholangitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2017 According to a DURECT Corporation media release, protocol has been reviewed by the FDA and IND is now open and the company is targeting dosing our first patient by the end of 2017.
    • 27 Apr 2017 According to a DURECT Corporation media release, the company will initiate this trial in mid-2017.
    • 14 Mar 2017 According to a DURECT Corporation media release, primary sclerosing cholangitis (PSC) likely the first oral indication to be pursued for DUR-928.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top